WUSTL spinout Wugen has collected $172m in a series B round to progress its pipeline targeting several cancer indications.

Wugen, a US-based oncology therapy developer spun out of Washington University in St Louis, closed a $172m series B round co-led by Abingworth and Tybourne Capital Management on Thursday.
Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, took part in the round, as did financial services group Fidelity, Intermediate Capital Group (ICG), Sands Capital, Aisling Capital Management, Velosity Capital, Falcon Edge Capital, RiverVest Venture Partners, Lyzz Capital and Lightchain…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?